CBD-loaded NPs increases glucose uptake and attenuates palmitate-induced lipid accumulation in human HepG2 hepatocytes

  1. Mazen M El-Hammadi 5
  2. Javier Vázquez Bourgon 67
  3. Esther Berrocoso Dominguez 127
  4. Benedicto Crespo Facorro 67
  5. Irene Suárez Pereira 247
  6. Lucía Martín Banderas 5
  1. 1 Neuropsychopharmacology & Psychobiology Research Group, Department of Psychology, University of Cadiz, Cádiz, Spain
  2. 2 Biomedical Research and Innovation Institute of Cádiz (INiBICA) Research Unit, Puerta del Mar UniversityHospital, University of Cádiz, Cádiz, Spain
  3. 3 Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBIS, Sevilla, Spain
  4. 4 Neuropsychopharmacology & Psychobiology Research Group, Department of Neuroscience, University ofCadiz, Cádiz, Spain
  5. 5 Department of Pharmacy and Pharmaceutical Technology, Facultad de Farmacia, Universidad de Sevilla, c/ Prof. García González nº2 41012, Sevilla, Spain.
  6. 6 Department of Psychiatry, School of Medicine, University Hospital Marqués de Valdecilla - IDIVAL, Santander, Spain.
  7. 7 Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain.
Mostrar afiliaciones +
Revista:
RESCIFAR Revista Española de Ciencias Farmacéuticas

ISSN: 2660-6356

Año de publicación: 2021

Título del ejemplar: XV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE FARMACIA INDUSTRIA Y GALÉNICA

Volumen: 2

Número: 2

Páginas: 200-201

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Otras publicaciones en: RESCIFAR Revista Española de Ciencias Farmacéuticas

Resumen

Cannabidiol (CBD) is a non-psychoactive cannabinoid that exhibits pain relief, anti-inflammatory, anti-oxidant, anti-tumor and neuroprotective properties. Furthermore, many studies have concluded that CBD exhibits several effects on both lipid and glucose metabolism through its action on various receptors and several metabolites. Accordingly, it has been found to decrease total cholesterol levels and to increase HDL levels, reduce intracellular lipid content and attenuate liver steatosis. Additionally, CBD has shown the ability to alleviate the symptoms of insulin resistance, minimize incidence of diabetes in mice and reduce the possibility of the metabolic syndrome among cannabis users. So, the objective of present work is to prepare CBD-loaded PLGA nanoparticles (NPs) and test their ability to increase glucose uptake and inhibit lipid accumulation in human HepG2 hepatocytes.

Fuente de los datos: Dialnet